Macque

该计划项目的长期目标是开发针对粘膜SIV（和HIV）的疫苗策略 传播，特别侧重于查明导致 保护B细胞发育和抗体产生。 灵长类核心的目标是提供实验动物和支持 为促进有效完成项目1、2、3和4所列目标提供所需的服务。 这将包括提供来自耶基斯恒河猴的无逆转录病毒成年雌性恒河猴 猕猴繁殖群;使用各种免疫平台进行免疫（项目1和2） 样本采集（适用于所有项目）以及SIVsmE 660的重复低剂量阴道挑战。灵长 核心任务还包括对实验动物的日常监测;定期体检， 用于免疫学和病毒学评价的血液采集以及样本的采购/运输 计划项目调查员;根据需要进行CBC和实验室分析;执行 项目3和项目4的安乐死与样本收集和处理;以及 以及对在试验过程中死亡或处死的所有实验动物进行组织学尸检评价。 本研究 提供这些资源和支援服务，将有助发展和测试新的艾滋病 本项目提出的疫苗概念。灵长类核心将在发展中发挥关键作用 预防SIV和HIV粘膜传播和致病性的疫苗的研究以及 这种保护的相关性。疫苗效力将通过其以下能力进行评价：1）预防获得 感染（灭菌免疫）或2）显著 控制攻击后的病毒血症和保护性免疫应答。

The long-range goal of this Program Project is to develop vaccine strategies against mucosal SIV (and HIV in the future) transmission, with a special focus on identifying local and systemic mechanisms leading to protecfive B cell development and antibody production. The objectives for the Primate Core are to provide the experimental animals and support services needed to facilitate the efficient completion of the aims outlined in Project 1, 2, 3 and 4. This will include the provision of retrovirus-free adult female rhesus macaques from the Yerkes rhesus macaque breeding colonies; immunizafions using the various immunizafion platforms (Projects 1 and 2) sample collections (for all projects) and repeated low dose vaginal challenges with SIVsmE660. The Primate Core tasks also include daily monitoring ofthe experimental animals; periodic physical examinafions with blood collecfions for immunologic and virologic evaluations and procurement/shipment of samples to the Program Project invesfigators; the performance of CBCs and laboratory analyses as needed; Perform euthanasia with sample collecfion and processing for Projects 3 and 4; and the performance of a basic gross and histologic necropsy evaluations of all experimental animals that die or are sacrificed during the course of this study. Provision of these resources and support services will facilitate the development and testing of novel AIDS vaccine concepts proposed in this Program Project. The Primate Core will play a key role in the development of a vaccine to prevent mucosal transmission and pathogenicity of SIV and HIV and the determination Of correlates of such protection. Vaccine efficacy will be evaluated by its ability to 1) prevent acquisition of infecfion (sterilizing immunity) or 2) significant control of viremia post-challenge and preservation of protective immune responses.